Progenics Pharmaceuticals Stock Price, News & Analysis (NASDAQ:PGNX)

$6.07 +0.23 (+3.94 %)
(As of 02/22/2018 04:00 PM ET)
Previous Close$5.84
Today's Range$5.71 - $6.08
52-Week Range$4.60 - $11.72
Volume1.78 million shs
Average Volume1.17 million shs
Market Capitalization$408.27 million
P/E Ratio-7.68
Dividend YieldN/A
Beta3.4

About Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals logoProgenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.

Receive PGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:PGNX
CUSIP74318710
Phone+1-646-9752500

Debt

Debt-to-Equity Ratio0.80%
Current Ratio7.86%
Quick Ratio7.86%

Price-To-Earnings

Trailing P/E Ratio-7.68354430379747
Forward P/E Ratio-6.60
P/E GrowthN/A

Sales & Book Value

Annual Sales$69.43 million
Price / Sales6.14
Cash Flow$0.19 per share
Price / Cash32.59
Book Value$1.50 per share
Price / Book4.05

Profitability

Trailing EPS($0.79)
Net Income$10.80 million
Net Margins-445.81%
Return on Equity-67.61%
Return on Assets-31.51%

Miscellaneous

Employees58
Outstanding Shares70,270,000

Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions

What is Progenics Pharmaceuticals' stock symbol?

Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."

How were Progenics Pharmaceuticals' earnings last quarter?

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) released its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.24) by $0.02. The biotechnology company had revenue of $2.70 million for the quarter, compared to analysts' expectations of $3.58 million. Progenics Pharmaceuticals had a negative net margin of 445.81% and a negative return on equity of 67.61%. The firm's revenue for the quarter was down 95.0% compared to the same quarter last year. During the same period last year, the company earned $0.52 EPS. View Progenics Pharmaceuticals' Earnings History.

When will Progenics Pharmaceuticals make its next earnings announcement?

Progenics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March, 8th 2018. View Earnings Estimates for Progenics Pharmaceuticals.

Where is Progenics Pharmaceuticals' stock going? Where will Progenics Pharmaceuticals' stock price be in 2018?

4 Wall Street analysts have issued 1-year price objectives for Progenics Pharmaceuticals' stock. Their predictions range from $12.00 to $15.00. On average, they expect Progenics Pharmaceuticals' stock price to reach $13.75 in the next year. View Analyst Ratings for Progenics Pharmaceuticals.

What are Wall Street analysts saying about Progenics Pharmaceuticals stock?

Here are some recent quotes from research analysts about Progenics Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. " (1/6/2018)
  • 2. Cantor Fitzgerald analysts commented, "PGNX has completed the rolling NDA for AZEDRA for pheochromocytoma and paraganglioma." (11/2/2017)

Who are some of Progenics Pharmaceuticals' key competitors?

Who are Progenics Pharmaceuticals' key executives?

Progenics Pharmaceuticals' management team includes the folowing people:

  • Peter J. Crowley, Independent Chairman of the Board (Age 59)
  • Mark R. Baker J.D., , Chief Executive Officer, Director (Age 62)
  • Patrick Fabbio, Chief Financial Officer, Senior Vice President (Age 49)
  • Vivien Wong Ph.D., Executive Vice President - Development (Age 60)
  • Jeffrey D. Summer, Senior Vice President - Strategy and Performance (Age 57)
  • Bryce Tenbarge, Vice President - Commercial (Age 44)
  • Bradley L. Campbell, Independent Director (Age 41)
  • Karen Jean Ferrante M.D., Independent Director (Age 59)
  • Michael D. Kishbauch, Independent Director (Age 68)
  • David A. Scheinberg MD., Ph.D., Independent Director (Age 61)

Who owns Progenics Pharmaceuticals stock?

Progenics Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.23%), Carillon Tower Advisers Inc. (5.21%), Pinnacle Associates Ltd. (3.15%), Ardsley Advisory Partners (2.60%), Phocas Financial Corp. (2.05%) and Rice Hall James & Associates LLC (1.97%). View Institutional Ownership Trends for Progenics Pharmaceuticals.

Who sold Progenics Pharmaceuticals stock? Who is selling Progenics Pharmaceuticals stock?

Progenics Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Pinnacle Associates Ltd., TIAA CREF Investment Management LLC, Fuller & Thaler Asset Management Inc., Ardsley Advisory Partners, Royce & Associates LP, Phocas Financial Corp. and Bank of New York Mellon Corp. View Insider Buying and Selling for Progenics Pharmaceuticals.

Who bought Progenics Pharmaceuticals stock? Who is buying Progenics Pharmaceuticals stock?

Progenics Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., BlackRock Inc., Landscape Capital Management L.L.C., Arizona State Retirement System, Rice Hall James & Associates LLC, Perceptive Advisors LLC, Fisher Asset Management LLC and Creative Planning. View Insider Buying and Selling for Progenics Pharmaceuticals.

How do I buy Progenics Pharmaceuticals stock?

Shares of Progenics Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Progenics Pharmaceuticals' stock price today?

One share of Progenics Pharmaceuticals stock can currently be purchased for approximately $6.07.

How big of a company is Progenics Pharmaceuticals?

Progenics Pharmaceuticals has a market capitalization of $408.27 million and generates $69.43 million in revenue each year. The biotechnology company earns $10.80 million in net income (profit) each year or ($0.79) on an earnings per share basis. Progenics Pharmaceuticals employs 58 workers across the globe.

How can I contact Progenics Pharmaceuticals?

Progenics Pharmaceuticals' mailing address is 1 World Trade Ctr Fl 47, NEW YORK, NY 10007-0089, United States. The biotechnology company can be reached via phone at +1-646-9752500 or via email at [email protected]


MarketBeat Community Rating for Progenics Pharmaceuticals (PGNX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  216 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  378
MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Progenics Pharmaceuticals (NASDAQ:PGNX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.253.253.203.17
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $13.75$13.75$13.20$12.83
Price Target Upside: 123.58% upside123.58% upside113.25% upside122.80% upside

Progenics Pharmaceuticals (NASDAQ:PGNX) Consensus Price Target History

Price Target History for Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals (NASDAQ:PGNX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/17/2018Cantor FitzgeraldReiterated RatingBuy$15.00LowView Rating Details
9/1/2017Needham & Company LLCReiterated RatingStrong-Buy$14.00MediumView Rating Details
8/22/2017AegisReiterated RatingBuy$14.00LowView Rating Details
6/8/2017Jefferies GroupReiterated RatingBuy$12.00HighView Rating Details
11/30/2016BTIG ResearchBoost Price TargetBuy$9.00 -> $11.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$11.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Progenics Pharmaceuticals (NASDAQ:PGNX) Earnings History and Estimates Chart

Earnings by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals (NASDAQ PGNX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018($0.23)N/AView Earnings Details
11/2/2017Q3 2017($0.24)($0.22)$3.58 million$2.70 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.20)($0.24)$3.34 million$2.77 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.16)($0.23)$4.50 million$2.40 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.20)($0.10)$4.43 million$4.65 millionViewListenView Earnings Details
11/7/2016Q316$0.55$0.52$52.90 million$53.90 millionViewListenView Earnings Details
8/4/2016Q216($0.13)($0.08)$6.33 million$8.50 millionViewN/AView Earnings Details
5/5/2016Q116($0.13)($0.18)$3.27 million$2.50 millionViewListenView Earnings Details
3/11/2016Q415($0.14)($0.10)$2.25 million$5.10 millionViewListenView Earnings Details
11/9/2015Q315($0.13)($0.14)$2.35 million$1.40 millionViewListenView Earnings Details
8/6/2015Q215($0.15)($0.17)$1.63 million$1.90 millionViewListenView Earnings Details
5/6/2015Q115($0.16)($0.15)$1.30 million$0.25 millionViewN/AView Earnings Details
3/16/2015Q414($0.13)($0.18)$2.87 million($0.57) millionViewN/AView Earnings Details
11/7/2014Q314($0.16)$0.51$2.50 million$41.66 millionViewN/AView Earnings Details
8/8/2014Q214($0.14)($0.17)$2.83 million$1.50 millionViewListenView Earnings Details
5/9/2014Q114($0.15)($0.15)$2.88 million$1.80 millionViewN/AView Earnings Details
3/13/2014Q4($0.19)($0.14)$1.48 million$3.00 millionViewListenView Earnings Details
3/3/2014Q4 2013($0.19)($0.14)$1.74 million$2.97 millionViewN/AView Earnings Details
11/11/2013Q313($0.22)($0.17)$2.00 million$0.90 millionViewN/AView Earnings Details
8/9/2013Q2 2013($0.24)($0.24)$1.86 million$1.80 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.19)($0.22)$1.71 million$2.23 millionViewN/AView Earnings Details
3/15/2013Q4 2012($0.31)($0.01)$1.16 million$8.87 millionViewN/AView Earnings Details
11/8/2012Q312($0.30)($0.33)$2.52 million$1.10 millionViewN/AView Earnings Details
8/9/2012($0.32)($0.32)ViewN/AView Earnings Details
5/8/2012($0.33)($0.39)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.25)($0.32)ViewN/AView Earnings Details
11/9/2011($0.33)($0.34)ViewN/AView Earnings Details
8/9/2011($0.25)$1.64ViewN/AView Earnings Details
5/10/2011($0.51)($0.69)ViewN/AView Earnings Details
3/15/2011($0.57)($0.57)ViewN/AView Earnings Details
11/8/2010Q3 2010($0.56)($0.52)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.54)($0.47)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.41)($0.58)ViewN/AView Earnings Details
3/15/2010Q4 2009($0.14)($0.02)ViewN/AView Earnings Details
11/9/2009Q3 2009($0.44)($0.41)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.50)($0.50)ViewN/AView Earnings Details
5/11/2009Q1 2009($0.27)($0.06)ViewN/AView Earnings Details
3/13/2009Q4 2008($0.30)($0.49)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.28)($0.41)ViewN/AView Earnings Details
8/8/2008Q2 2008$0.01($0.08)ViewN/AView Earnings Details
5/9/2008Q1 2008($0.41)($0.52)ViewN/AView Earnings Details
3/17/2008Q4 2007($0.46)($0.53)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Progenics Pharmaceuticals (NASDAQ:PGNX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.92 EPS
Next Year EPS Consensus Estimate: $-0.63 EPS

Dividends

Dividend History for Progenics Pharmaceuticals (NASDAQ:PGNX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Progenics Pharmaceuticals (NASDAQ PGNX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.63%
Institutional Ownership Percentage: 88.54%
Insider Trades by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)
Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals (NASDAQ PGNX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2017Healthcare Master Fun BroadfinMajor ShareholderSell602,600$9.66$5,821,116.00View SEC Filing  
2/9/2017Healthcare Master Fun BroadfinMajor ShareholderSell351,300$9.71$3,411,123.00View SEC Filing  
6/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  
3/13/2015Robert J IsraelEVPSell3,000$7.00$21,000.00View SEC Filing  
3/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  
3/3/2015Robert J IsraelEVPSell5,000$6.49$32,450.00View SEC Filing  
1/12/2015Robert J IsraelEVPSell2,000$7.06$14,120.00View SEC Filing  
12/11/2014Robert J IsraelEVPSell3,000$7.07$21,210.00View SEC Filing  
11/21/2014Robert J IsraelEVPSell9,000$7.00$63,000.00View SEC Filing  
11/13/2014Robert J IsraelEVPSell10,000$6.83$68,300.00View SEC Filing  
11/11/2014Robert J IsraelEVPSell5,000$6.53$32,650.00View SEC Filing  
7/21/2014Healthcare Master Fun BroadfinMajor ShareholderBuy1,625,436$4.60$7,477,005.60View SEC Filing  
7/18/2014Healthcare Master Fun BroadfinMajor ShareholderBuy388,200$4.73$1,836,186.00View SEC Filing  
7/17/2014Healthcare Master Fun BroadfinMajor ShareholderBuy436,884$4.48$1,957,240.32View SEC Filing  
7/16/2014Healthcare Master Fun BroadfinMajor ShareholderBuy411,693$4.48$1,844,384.64View SEC Filing  
7/18/2013Robert J IsraelVPSell5,000$6.33$31,650.00View SEC Filing  
2/27/2013Mark Robert BakerCEOBuy1,262$2.72$3,432.64View SEC Filing  
1/22/2013Mark Robert BakerCEOBuy1,215$2.82$3,426.30View SEC Filing  
12/26/2012Mark Robert BakerCEOBuy1,142$3.01$3,437.42View SEC Filing  
11/28/2012Mark Robert BakerCEOBuy1,607$2.13$3,422.91View SEC Filing  
11/19/2012Mark Robert BakerCEOBuy11,800$1.96$23,128.00View SEC Filing  
11/16/2012Mark Robert BakerCEOBuy49,793$1.82$90,623.26View SEC Filing  
11/15/2012Mark Robert BakerCEOBuy48,833$1.69$82,527.77View SEC Filing  
10/24/2012Mark Robert BakerCEOBuy1,162$2.96$3,439.52View SEC Filing  
9/26/2012Mark Robert BakerCEOBuy1,036$3.32$3,439.52View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Progenics Pharmaceuticals (NASDAQ PGNX) News Headlines

Source:
DateHeadline
Progenics Pharmaceuticals (PGNX) Lifted to Hold at BidaskClubProgenics Pharmaceuticals (PGNX) Lifted to Hold at BidaskClub
www.americanbankingnews.com - February 18 at 1:00 PM
Progenics Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare ConferenceProgenics Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 15 at 4:46 PM
Progenics Pharmaceuticals Sees Unusually High Options Volume (PGNX)Progenics Pharmaceuticals Sees Unusually High Options Volume (PGNX)
www.americanbankingnews.com - February 14 at 5:50 PM
Progenics Pharmaceuticals (PGNX) Presents At BIO CEO & Investor Conference - SlideshowProgenics Pharmaceuticals (PGNX) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 14 at 3:27 PM
Progenics Pharmaceuticals to Present at the 2018 BIO CEO & Investor ConferenceProgenics Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 5 at 3:24 PM
Progenics Pharmaceuticals (PGNX) Stock Rating Lowered by BidaskClubProgenics Pharmaceuticals (PGNX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - February 3 at 11:58 AM
Progenics Pharmaceuticals, Inc. (PGNX) Given Consensus Recommendation of "Hold" by BrokeragesProgenics Pharmaceuticals, Inc. (PGNX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 3 at 5:28 AM
Progenics Pharma (PGNX) Announces Presentation of AZEDRA Biochemical Tumor Marker Data at ENDO - StreetInsider.comProgenics Pharma (PGNX) Announces Presentation of AZEDRA Biochemical Tumor Marker Data at ENDO - StreetInsider.com
www.streetinsider.com - February 2 at 6:28 AM
Progenics Pharmaceuticals Announces Presentation of AZEDRA® (iobenguane I 131) Biochemical Tumor Marker Data at the 2018 Endocrine Society (ENDO) Annual MeetingProgenics Pharmaceuticals Announces Presentation of AZEDRA® (iobenguane I 131) Biochemical Tumor Marker Data at the 2018 Endocrine Society (ENDO) Annual Meeting
feeds.benzinga.com - February 1 at 5:13 PM
Quotidian Technical Highlights on Selected Biotech Stocks -- PDL BioPharma, Progenics Pharma, Pain Therapeutics ... - PR Newswire (press release)Quotidian Technical Highlights on Selected Biotech Stocks -- PDL BioPharma, Progenics Pharma, Pain Therapeutics ... - PR Newswire (press release)
www.prnewswire.com - January 20 at 4:14 PM
Progenics Pharmaceuticals: An Underappreciated Company You Cant Afford To Ignore - Seeking AlphaProgenics Pharmaceuticals: An Underappreciated Company You Can't Afford To Ignore - Seeking Alpha
seekingalpha.com - January 20 at 4:14 PM
Cantor Fitzgerald Reiterates "Buy" Rating for Progenics Pharmaceuticals (PGNX)Cantor Fitzgerald Reiterates "Buy" Rating for Progenics Pharmaceuticals (PGNX)
www.americanbankingnews.com - January 18 at 1:50 PM
Progenics Pharmaceuticals, Inc. (PGNX) Receives Average Rating of "Buy" from AnalystsProgenics Pharmaceuticals, Inc. (PGNX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - January 9 at 8:12 AM
Progenics Pharmaceuticals (PGNX) Lowered to Hold at Zacks Investment ResearchProgenics Pharmaceuticals (PGNX) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 6 at 7:02 AM
Traders Buy High Volume of Progenics Pharmaceuticals Put Options (PGNX)Traders Buy High Volume of Progenics Pharmaceuticals Put Options (PGNX)
www.americanbankingnews.com - January 5 at 2:10 AM
Your Daily Pharma Scoop: Progenics Azerda Update, Atara Gets FDA Clearance For Phase 3 Trial, Avadel Provides ... - Seeking AlphaYour Daily Pharma Scoop: Progenics Azerda Update, Atara Gets FDA Clearance For Phase 3 Trial, Avadel Provides ... - Seeking Alpha
seekingalpha.com - January 2 at 10:09 AM
Progenics Pharma (PGNX) Reports Completion of Enrollment in Phase 3 Study of PSMA-Targeted Imaging Agent 1404 - StreetInsider.comProgenics Pharma (PGNX) Reports Completion of Enrollment in Phase 3 Study of PSMA-Targeted Imaging Agent 1404 - StreetInsider.com
www.streetinsider.com - January 2 at 10:09 AM
Progenics Pharmaceuticals Completes Enrollment in Phase 3 Study of PSMA-Targeted Imaging Agent 1404Progenics Pharmaceuticals Completes Enrollment in Phase 3 Study of PSMA-Targeted Imaging Agent 1404
finance.yahoo.com - January 2 at 10:09 AM
Progenics Pharmaceuticals Target of Unusually High Options Trading (PGNX)Progenics Pharmaceuticals Target of Unusually High Options Trading (PGNX)
www.americanbankingnews.com - January 1 at 2:28 AM
Goldman Sachs and Hess slide while PepsiCo and TiVo riseGoldman Sachs and Hess slide while PepsiCo and TiVo rise
marketbeat.com - December 29 at 5:31 PM
Why Progenics Pharmaceuticals, Inc.'s Shareholders Came to Their SensesWhy Progenics Pharmaceuticals, Inc.'s Shareholders Came to Their Senses
finance.yahoo.com - December 29 at 4:34 PM
Progenics Pharmaceuticals Inc. (PGNX) Has Jumped To Over A 2-Month HighProgenics Pharmaceuticals Inc. (PGNX) Has Jumped To Over A 2-Month High
www.nasdaq.com - December 29 at 10:28 AM
Progenics Pharma (PGNX) Reports FDA Acceptance of New Drug Application for AZEDRA (iobenguane I 131) in Pheochromocytoma and ParagangliomaProgenics Pharma (PGNX) Reports FDA Acceptance of New Drug Application for AZEDRA (iobenguane I 131) in Pheochromocytoma and Paraganglioma
www.streetinsider.com - December 29 at 10:28 AM
Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA® (iobenguane I 131) in Pheochromocytoma and ParagangliomaProgenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA® (iobenguane I 131) in Pheochromocytoma and Paraganglioma
finance.yahoo.com - December 29 at 10:28 AM
Progenics Pharma Surges on FDA DecisionProgenics Pharma Surges on FDA Decision
finance.yahoo.com - December 29 at 10:28 AM
Progenics shares jump 21% premarket after FDA says it will review treatment for rare cancerProgenics shares jump 21% premarket after FDA says it will review treatment for rare cancer
finance.yahoo.com - December 29 at 10:28 AM
ETFs with exposure to Progenics Pharmaceuticals, Inc. : December 26, 2017ETFs with exposure to Progenics Pharmaceuticals, Inc. : December 26, 2017
finance.yahoo.com - December 27 at 1:07 PM
Progenics: The Successful Trial That (Some Claim) Has Failed - Seeking AlphaProgenics: The Successful Trial That (Some Claim) Has Failed - Seeking Alpha
seekingalpha.com - December 24 at 7:37 PM
Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US : December 22, 2017Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US : December 22, 2017
finance.yahoo.com - December 22 at 10:27 AM
Progenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017Progenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017
finance.yahoo.com - December 22 at 10:27 AM
Progenics Pharmaceuticals Inc. (PGNX) Given Average Rating of "Buy" by AnalystsProgenics Pharmaceuticals Inc. (PGNX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - December 15 at 6:22 AM
Progenics Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PGNX) : December 12, 2017Progenics Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PGNX) : December 12, 2017
finance.yahoo.com - December 12 at 4:57 PM
Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US : December 11, 2017Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US : December 11, 2017
finance.yahoo.com - December 11 at 11:01 AM
Progenics Pharmaceuticals (PGNX) Rating Increased to Hold at ValuEngineProgenics Pharmaceuticals (PGNX) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - December 9 at 5:08 PM
Progenics Pharmaceuticals (PGNX) Raised to "Hold" at BidaskClubProgenics Pharmaceuticals (PGNX) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - December 9 at 7:02 AM
Why Progenics Pharmaceuticals Inc’s (PGNX) Ownership Structure Is ImportantWhy Progenics Pharmaceuticals Inc’s (PGNX) Ownership Structure Is Important
finance.yahoo.com - December 8 at 10:17 AM
Whats Happening With These Biotech Stocks? -- Opko Health, Kura Oncology, PDL BioPharma, and Progenics PharmaWhat's Happening With These Biotech Stocks? -- Opko Health, Kura Oncology, PDL BioPharma, and Progenics Pharma
www.bizjournals.com - December 7 at 10:42 AM
Progenics Pharmaceuticals Inc. (PGNX) Receives Average Recommendation of "Hold" from AnalystsProgenics Pharmaceuticals Inc. (PGNX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 20 at 3:36 AM
Estimating The Fair Value Of Progenics Pharmaceuticals Inc (PGNX)Estimating The Fair Value Of Progenics Pharmaceuticals Inc (PGNX)
finance.yahoo.com - November 20 at 2:30 AM
Progenics Pharmaceuticals (PGNX) Presents At Jefferies 2017 London Healthcare Conference - SlideshowProgenics Pharmaceuticals (PGNX) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 18 at 10:54 AM
Oversold Conditions For Progenics Pharmaceuticals (PGNX)Oversold Conditions For Progenics Pharmaceuticals (PGNX)
www.thestreet.com - November 15 at 7:25 AM
Financial Analysis: Progenics Pharmaceuticals (PGNX) and The CompetitionFinancial Analysis: Progenics Pharmaceuticals (PGNX) and The Competition
www.americanbankingnews.com - November 13 at 11:28 AM
Progenics Pharmaceuticals Inc. (PGNX) Forecasted to Post FY2017 Earnings of ($0.93) Per ShareProgenics Pharmaceuticals Inc. (PGNX) Forecasted to Post FY2017 Earnings of ($0.93) Per Share
www.americanbankingnews.com - November 8 at 10:54 AM
Progenics Pharmaceuticals: Prospects Look Bright - Seeking AlphaProgenics Pharmaceuticals: Prospects Look Bright - Seeking Alpha
seekingalpha.com - November 4 at 8:52 AM
Progenics Pharmaceuticals Completes Submission of NDA for AZEDRA® (iobenguane I 131) in Pheochromocytoma and ParagangliomaProgenics Pharmaceuticals Completes Submission of NDA for AZEDRA® (iobenguane I 131) in Pheochromocytoma and Paraganglioma
finance.yahoo.com - November 4 at 8:52 AM
Progenics Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business UpdateProgenics Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Update
finance.yahoo.com - November 4 at 8:52 AM
Progenics reports 3Q lossProgenics reports 3Q loss
finance.yahoo.com - November 4 at 8:52 AM
Edited Transcript of PGNX earnings conference call or presentation 2-Nov-17 12:30pm GMTEdited Transcript of PGNX earnings conference call or presentation 2-Nov-17 12:30pm GMT
finance.yahoo.com - November 4 at 8:52 AM
Progenics Pharmaceuticals Inc. (PGNX) Issues  Earnings ResultsProgenics Pharmaceuticals Inc. (PGNX) Issues Earnings Results
www.americanbankingnews.com - November 3 at 6:25 PM
Progenics Pharmaceuticals Inc. (PGNX) Receives "Buy" Rating from Cantor FitzgeraldProgenics Pharmaceuticals Inc. (PGNX) Receives "Buy" Rating from Cantor Fitzgerald
www.americanbankingnews.com - November 2 at 11:02 AM

SEC Filings

Progenics Pharmaceuticals (NASDAQ:PGNX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Progenics Pharmaceuticals (NASDAQ:PGNX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Progenics Pharmaceuticals (NASDAQ PGNX) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.